Literature DB >> 21352258

EGFR in melanoma: clinical significance and potential therapeutic target.

Barbara Boone1, Koen Jacobs, Liesbeth Ferdinande, Jasmien Taildeman, Jo Lambert, Marc Peeters, Marc Bracke, Patrick Pauwels, Lieve Brochez.   

Abstract

BACKGROUND: The role of epidermal growth factor receptor (EGFR) has been established in a range of neoplasms. In melanoma, data on EGFR protein expression are conflicting. Fluorescence in situ hybridization (FISH) analysis for EGFR gene expression in melanoma showed EGFR gene amplification to be linked with worse prognosis. Cetuximab has been shown to suppress the formation of metastasis in mice.
METHODS: EGFR protein expression and gene copy number status were evaluated by means of immunohistochemistry and FISH in melanoma samples of patients with known clinicopathological data. Associations between EGFR expression and prognostic parameters were investigated. The effect of different cetuximab concentrations on the BLM melanoma cell line was evaluated by means of methyl tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays.
RESULTS: EGFR protein expression was more frequently observed in patients with a positive sentinel lymph node. However, EGFR immunostaining has no predictive value. The presence of EGFR polysomy was associated with thicker tumors. Treatment of the BLM melanoma cell line with different concentrations of cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth.
CONCLUSION: EGFR appears to be involved in progression and metastasis of a subset of melanomas. Targeting EGFR could therefore represent a therapeutic option for these melanomas.
Copyright © 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352258     DOI: 10.1111/j.1600-0560.2011.01673.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  32 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

3.  A quantitative method for screening and identifying molecular targets for nanomedicine.

Authors:  Peng Guo; Jiang Yang; Diane R Bielenberg; Deborah Dillon; David Zurakowski; Marsha A Moses; Debra T Auguste
Journal:  J Control Release       Date:  2017-03-22       Impact factor: 9.776

4.  Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.

Authors:  Matthew A Smith; Richard Hall; Kate Fisher; Scott M Haake; Farah Khalil; Matthew B Schabath; Vincent Vuaroqueaux; Heinz-Herbert Fiebig; Soner Altiok; Yian Ann Chen; Eric B Haura
Journal:  Sci Signal       Date:  2015-01-13       Impact factor: 8.192

5.  Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Authors:  Tamás Garay; Eszter Molnár; Éva Juhász; Viktória László; Tamás Barbai; Judit Dobos; Karin Schelch; Christine Pirker; Michael Grusch; Walter Berger; József Tímár; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2015-03-09       Impact factor: 3.201

6.  p120-catenin down-regulation and epidermal growth factor receptor overexpression results in a transformed epithelium that mimics esophageal squamous cell carcinoma.

Authors:  Heather L Lehman; Xuebin Yang; Patricia A Welsh; Douglas B Stairs
Journal:  Am J Pathol       Date:  2015-01       Impact factor: 4.307

7.  Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Authors:  Caroline Bonet; Sandy Giuliano; Mickaël Ohanna; Karine Bille; Maryline Allegra; Jean-Philippe Lacour; Philippe Bahadoran; Stéphane Rocchi; Robert Ballotti; Corine Bertolotto
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

8.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

9.  Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression.

Authors:  Jong Y Park; Ernest K Amankwah; Gabriella M Anic; Hui-Yi Lin; Brooke Walls; Hyun Park; Kevin Krebs; Melissa Madden; Kristen Maddox; Suroosh Marzban; Shenying Fang; Wei Chen; Jeffrey E Lee; Qingyi Wei; Christopher I Amos; Jane L Messina; Vernon K Sondak; Thomas A Sellers; Kathleen M Egan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

10.  Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Authors:  Alexander Gross; Annett Niemetz-Rahn; Anika Nonnenmacher; Johannes Tucholski; Ulrich Keilholz; Alberto Fusi
Journal:  Target Oncol       Date:  2014-05-15       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.